These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20668267)

  • 21. Provenge: combating prostate cancer with a vengeance?
    Schwaab T; Pili R
    Expert Rev Vaccines; 2011 Aug; 10(8):1113-4. PubMed ID: 21854304
    [No Abstract]   [Full Text] [Related]  

  • 22. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
    McBride D
    ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
    [No Abstract]   [Full Text] [Related]  

  • 23. Business barriers slowing the pace of cancer immunotherapy research and development.
    Tuma RS
    J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
    [No Abstract]   [Full Text] [Related]  

  • 24. A shot in the arm for cancer vaccines?
    Ledford H
    Nature; 2010 Apr; 464(7292):1110-1. PubMed ID: 20414279
    [No Abstract]   [Full Text] [Related]  

  • 25. Cancer vaccine approval could open floodgates.
    Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296
    [No Abstract]   [Full Text] [Related]  

  • 26. Uncertainty surrounds cancer vaccine review at FDA.
    Fox JL
    Nat Biotechnol; 2007 Aug; 25(8):827-8. PubMed ID: 17687346
    [No Abstract]   [Full Text] [Related]  

  • 27. Two years of Provenge.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Apr; 8(4):505. PubMed ID: 22832253
    [No Abstract]   [Full Text] [Related]  

  • 28. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
    Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R
    N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880
    [No Abstract]   [Full Text] [Related]  

  • 29. Cabazitaxel in prostate cancer: stretching a string.
    Dorff TB; Quinn DI
    Lancet; 2010 Oct; 376(9747):1119-20. PubMed ID: 20888974
    [No Abstract]   [Full Text] [Related]  

  • 30. First biosimilar drug approved for sale in the United States.
    Hede K
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444
    [No Abstract]   [Full Text] [Related]  

  • 31. A prostate cancer 'vaccine' under development.
    Mayo Clin Health Lett; 2009 Dec; 27(12):4. PubMed ID: 20082492
    [No Abstract]   [Full Text] [Related]  

  • 32. The first dendritic cell-based therapeutic cancer vaccine is approved by the FDA.
    Hovden AO; Appel S
    Scand J Immunol; 2010 Dec; 72(6):554. PubMed ID: 21044130
    [No Abstract]   [Full Text] [Related]  

  • 33. Straight talk from... Jim Young. Interview by Apoorva Mandavilli.
    Young J
    Nat Med; 2007 May; 13(5):524. PubMed ID: 17479087
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
    Masters GA; Krilov L; Bailey HH; Brose MS; Burstein H; Diller LR; Dizon DS; Fine HA; Kalemkerian GP; Moasser M; Neuss MN; O'Day SJ; Odenike O; Ryan CJ; Schilsky RL; Schwartz GK; Venook AP; Wong SL; Patel JD
    J Clin Oncol; 2015 Mar; 33(7):786-809. PubMed ID: 25605863
    [No Abstract]   [Full Text] [Related]  

  • 35. Designing smarter cancer prevention trials.
    Jonietz E
    Nature; 2011 Mar; 471(7339):S20-1. PubMed ID: 21430717
    [No Abstract]   [Full Text] [Related]  

  • 36. Citizenship in our profession.
    Droller MJ
    J Urol; 2010 Oct; 184(4):1248-50. PubMed ID: 20723933
    [No Abstract]   [Full Text] [Related]  

  • 37. Sipuleucel-T (APC8015) for prostate cancer.
    So-Rosillo R; Small EJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer vaccine competition wide open as agents move rapidly into clinical arena.
    Reynolds T
    J Natl Cancer Inst; 1999 Feb; 91(4):309-12. PubMed ID: 10050861
    [No Abstract]   [Full Text] [Related]  

  • 40. Death threats for discrepancies over treatment data.
    Burton A
    Lancet Oncol; 2007 Jul; 8(7):577. PubMed ID: 17668482
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.